A new study demonstrates a way to stop the influenza virus from leaping from one host to the next while continuing to keep the virus from replicating inside the host.
The U.S. Food and Drug Administration has expanded the approved age indication of AREXVY to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV.
According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Researchers have developed a bandage-like microneedle patch that samples key cells often missed in routine blood samples and biopsies without the need for taking blood or surgical biopsies.
Researchers have discovered why the unusual side effect of a blood clot that impacted some recipients of the Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines occurred.
Stanford Medicine researchers have invented a new vaccine that protects mice from respiratory viruses, bacteria and allergens, which is the closest yet to a universal vaccine.
The U.S. Food and Drug Administration has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia.
A vaccine candidate called GBP511 that builds upon a self-assembling nanoparticle technology has begun human clinical testing in Australia.
FDA has granted fast track designation to gamgertamig (OM336) for the treatment of immune thrombocytopenia and cold and warm autoimmune hemolytic anemia.
A clinical tria that evaluated an alpha-lactalbumin (aLA) vaccine demonstrated an immune response in 74 percent of patients who presently have or are at high risk for triple-negative breast cancer.
A study has identified, for the first time, a case of spontaneous correction of a genetic mutation in a patient with CD137 deficiency, a rare immunodeficiency that causes vulnerability to Epstein–Barr virus infection.
GAMMAGARD LIQUID ERC (immune globulin infusion [human]) with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, is now available in the U.S.